Seraxis Secures $40 Million in Series C Funding to Revolutionize Diabetes Management

In a significant milestone for the advancement of diabetes care, Seraxis has successfully secured $40 million in funding to further develop its groundbreaking islet replacement therapy, SR-02. This innovative program targets millions around the globe who are grappling with insulin-requiring diabetes and the life-threatening complications that accompany it. Founded on the belief that transformative therapies can dramatically enhance patient quality of life, Seraxis is on a mission to revolutionize diabetes management with its cutting-edge solutions. The latest infusion of capital comes from a distinguished group of investors, including Frazier Life Sciences, Polaris Partners, Eli Lilly and Company, and the T1D Fund, all of whom share a vision for improved outcomes in diabetes care. The funding will primarily be directed toward advancing the SR-02 therapy, designed specifically for patients undergoing immunosuppression therapy, with the ultimate goal of creating a robust pipeline of follow-on therapies for individuals without the need for immune suppression. This capital injection not only underscores the growing confidence in Seraxis' innovative approach but also highlights the increasing urgency for new therapeutic strategies to combat the rising global diabetes crisis. By steering these funds into both clinical development and research initiatives, Seraxis is poised to make a monumental impact on the lives of those affected by diabetes, paving the way for a future where effective, life-altering treatments are accessible to all.